St Louis, MO Clinical Trials Report — July 2026

St. Louis residents who may qualify for a closing clinical trial should contact local research sites soon: 55 recruiting studies are expected to close within the next 90 days, including 10 that accept healthy volunteers. The city also has 1,347 recruiting trials across 422 research facilities, so participants have substantial choice—but enrollment can end early when a study reaches its target.

July brought 14 new trials, down from 28 in June and May’s 28. The new studies cover advanced and cutaneous squamous cell carcinoma, amyloid cardiomyopathy and amyloidosis, chronic lower back pain, cystic fibrosis, diabetic foot ulcers, GLP-1 agonists, and kidney transplantation.

Closing windows for St. Louis patients and volunteers

People seeking treatment studies should prioritize conditions with multiple trials approaching their projected closing dates. The largest groups include:

• Prostate cancer (3 trials)
• Alzheimer disease (2 trials)
• Endometrial cancer (2 trials)
• Lymphoma (2 trials)
• Acute stress disorder (2 trials)
• Neoplasms by histologic type (2 trials)
• Acute stress reaction (2 trials)
• Breast cancer (2 trials)
• Lupus nephritis (2 trials)
• Aggression (1 trial)

Of the 55 closing-soon studies, 10 accept healthy volunteers. Across St. Louis, 112 trials are currently recruiting healthy participants. Eligibility may still depend on age, medications, medical history, laboratory results, and time commitments, so people interested in volunteer studies should review screening requirements directly with the research team.

Notable July openings include Phase 2 and Phase 3 studies

Drug studies make up 11 of July’s new openings, joined by 3 device studies and one biological, diagnostic-test, and other-type study. Several late-stage trials offer opportunities for people with specific cancers, schizophrenia, muscular dystrophy, or chronic pain:

• NCT07680790 is a Phase 3 Bristol-Myers Squibb study enrolling 850 participants with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. It compares izalontamab brengitecan with osimertinib against osimertinib alone or osimertinib plus platinum-based chemotherapy.
• NCT07686263 is a Phase 3 KarXT relapse-prevention trial sponsored by Karuna Therapeutics, a Bristol Myers Squibb company. It plans to enroll 472 participants with schizophrenia.
• NCT07731256 is a Phase 2 Washington University School of Medicine study of semaglutide for chronic low back pain, with planned enrollment of 250 participants. The study examines whether a GLP-1 receptor agonist may help reduce pain through weight reduction and other mechanisms.
• NCT07678775 is a Phase 3 open-label extension study sponsored by ML Bio Solutions of BBP-418, also called ribitol, for people with limb-girdle muscular dystrophy type 2I/R9. Planned enrollment is 107 participants who previously took part in an earlier study.
• NCT07723651 is a Phase 2 Washington University School of Medicine imaging study involving [18F]fluorthanatrace PET and circulating tumor DNA to help predict response to PARP inhibitor therapy in metastatic prostate cancer. The study plans to enroll 75 participants.
• NCT07696338, sponsored by Nicole Hamblett, evaluates early airway-clearance approaches in cystic fibrosis through two parallel randomized studies involving hypertonic saline and dornase alfa. Planned enrollment is 405 participants.

Washington University School of Medicine sponsors 5 of the new studies, the largest sponsor group in July. Other sponsors include Boston University Charles River Campus, Bristol-Myers Squibb, Capsicure, Eidos Therapeutics, AstraZeneca, Karuna Therapeutics, and ML Bio Solutions. The new-trial mix includes 8 studies categorized as other, 5 industry-sponsored studies, and 1 network study.

Where St. Louis has the deepest research access

Washington University-affiliated sites dominate the local research landscape, particularly for cancer, neurology, transplant medicine, pain, rare disease, and other complex conditions. Washington University School of Medicine lists 438 recruiting trials, far more than any other named facility.

• Washington University School of Medicine (438 trials)
• Washington University (122 trials)
• Mercy Hospital Saint Louis (92 trials)
• Siteman Cancer Center-South County (84 trials)
• Mercy Hospital South (83 trials)
• Missouri Baptist Medical Center (80 trials)
• Siteman Cancer Center at Christian Hospital (78 trials)
• Washington University in St. Louis (74 trials)
• Research Site (50 trials)
• Mercy Infusion Center - Chippewa (35 trials)
• Cardinal Glennon Children's Medical Center (23 trials)
• Washington University School of Medicine in St. Louis (22 trials)

Patients should search across affiliated listings because the same health system may appear under several facility names. Siteman Cancer Center locations and Mercy hospitals provide additional access for oncology and hospital-based studies, while Cardinal Glennon is a notable option for pediatric research.

Eligibility and healthy-volunteer opportunities

None of the 14 new July trials accept healthy volunteers, even though 112 total healthy-volunteer studies are recruiting locally. Three new trials include children, one is male-only, none are female-only, and 12 include older adults. These figures make the broader existing trial pool more relevant for healthy participants than the month’s new openings.

People with active conditions should act first if they match one of the closing-soon categories, especially prostate cancer, breast cancer, lymphoma, endometrial cancer, Alzheimer disease, or lupus nephritis. Healthy volunteers should search the existing pool now rather than waiting for a new July opening.

Other Missouri cities to consider

Participants willing to travel can also look at nearby Missouri locations. Kansas City has 6 recruiting trials, while the City of Saint Peters and Columbia each have 1. These alternatives may be useful when a St. Louis study has restrictive eligibility, a long waitlist, or a closing enrollment window.

The recent decline from 31 new trials in February to 25 in March, 21 in April, 28 in May, 28 in June, and 14 in July suggests a smaller current flow of openings, while August data show 6 new trials in the available trend. Local sites continue to offer a large active portfolio, and upcoming changes in sponsor activity and enrollment deadlines may create new opportunities for St. Louis participants later in the summer.